BROWNSTEIN HYATT FARBER SCHRECK, LLP for NOVARTIS
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report (this page) | Oct 17, 2024 | $60,000 | Replaced |
| 3rd Quarter - Amendment | Oct 17, 2024 | $60,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to cell and gene therapy Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues S. 476/H.R.5547 The Maintaining Investments in New Innovations (MINI) Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| NADEAM ELSHAMI | — |
| EMILY FELDER | — |
| ZACHARY PFISTER | — |
| DAVID REID | — |
| ADAM STEINMETZ | — |
| DEEMA TARAZI | — |
| ANDREW USYK | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.